Chemomab Therapeutics Ltd. (CMMB)
Automate Your Wheel Strategy on CMMB
With Tiblio's Option Bot, you can configure your own wheel strategy including CMMB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CMMB
- Rev/Share 0.0
- Book/Share 0.0297
- PB 2.0555
- Debt/Equity 0.0239
- CurrentRatio 4.9845
- ROIC -1.0229
- MktCap 1150632.0
- FreeCF/Share 0.0
- PFCF 0.0
- PE -2.0765
- Debt/Assets 0.0191
- DivYield 0
- ROE -1.0081
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up T o 2041 — —Further Ex pands Protections Provided by Nebokitug 's Composition of Matter and Methods and Use Patents Issued in the U.S., Europe, Japan and A dditional Key Territories— TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its lead product nebokitug (formerly CM-101) has been awarded new patent protections …
Read More
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Chemomab reported new clinical data to be presented at EASL 2025 that further confirms the potential of nebokitug as a first-in-class treatment for PSC.
Read More
Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that clinical data on nebokitug (CM-101) for the treatment of patients with primary sclerosing cholangitis (PSC) will be presented at major upcoming scientific conferences including DDW25, Digestive Disease Week 2025®; EASL 2025, the Annual Congress of the European Association for the Study of the Liver; and BSG LIVE'25, the British Society of Gastroenterology's annual meeting.
Read More
Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
After End-of-Phase 2 meeting, Chemomab and FDA aligned on a clear pathway to regulatory approval—a single pivotal Phase 3 study for the treatment of PSC.
Read More
About Chemomab Therapeutics Ltd. (CMMB)
- IPO Date 2019-02-12
- Website https://www.chemomab.com
- Industry Biotechnology
- CEO Dr. Adi Mor George Ph.D.
- Employees 20